ArticleJGH open : an open access journal of gastroenterology and hepatology2025
Negative Impact of Coronavirus Disease 2019 Pandemic on Gastric Cancer Care in Japan: A Tokushukai Real-World Data Project 08 (TREAD 08).
Article in JGH open : an open access journal of gastroenterology and hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Negative Impact of Coronavirus Disease 2019 Pandemic on Gastric Cancer Care in Japan: A Tokushukai Real-World Data Project 08 (TREAD 08).JGH open : an open access journal of gastroenterology and hepatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Concerns regarding the adverse impact of coronavirus disease 2019 (COVID-19) on cancer care survival have been raised; however, clear evidence remains limited. Therefore, we aimed to investigate the influence of the COVID-19 pandemic on gastric cancer management in Japan using real-world data from the Tokushukai Real-World Data project. Methods and Results: This retrospective cohort study was conducted across 46 Tokushukai Medical Group hospitals in Japan, identifying patients newly diagnosed with gastric cancer between January 2017 and December 2022. Patients with active double cancers or non-epithelial tumors were excluded. We used data between January 2017 and March 2020 as the baseline (pre-COVID-19 period) to assess the changes in the number of diagnoses, screening detections, disease stage at diagnosis, and prognosis between April 2020 and December 2022 (mid-COVID-19 period). This study included 14 125 patients with 14 446 gastric cancer cases. Compared with the pre-COVID-19 period, the mid-COVID-19 period exhibited a 12% (95% confidence interval [CI]: 3%-20%) decrease in screening detections, a 9% (95% CI: 1%-18%) increase in metastatic stage detection, a 14% (95% CI: 7%-20%) decrease in curative surgery, and a 32% (95% CI: 19%-43%) decrease in radiation therapy. The analysis also revealed a 9.4% (95% CI: 2.0%-17.2%) increase in mortality in the mid-COVID-19 period compared with the pre-COVID-19 period. Conclusion: This nationwide, real-world study provides robust evidence that COVID-19 has reduced survival rates for Japanese patients with gastric cancer by disrupting diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.